GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK plc and CureVac N.V. have announced a restructuring of their existing collaboration into a new licensing agreement. GSK will gain full rights to develop, manufacture, and commercialize mRNA candidate vaccines for influenza and COVID-19 globally.

Under the terms, CureVac will receive €400 million upfront and up to €1.05 billion in development, regulatory, and sales milestones. The new agreement replaces all previous financial considerations from their prior collaboration.

Since 2020, GSK and CureVac have been developing mRNA vaccines for infectious diseases, with promising candidates for seasonal influenza and COVID-19 currently in Phase 2 clinical trials.

GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for developing best-in-class mRNA vaccines. CureVac's CEO, Alexander Zehnder, highlighted the strong financial position this agreement provides to focus on building a robust R&D pipeline.

The completion of the agreement is subject to antitrust and regulatory approvals and customary closing conditions.